Dihexa (PNB-0408) Nootropic powder (1401708-83-5)HPLC≥98%

www.wisepowder.com

wise12@wisepowder.com

Dihexa (PNB-0408) Nootropic powder (1401708-83-5)HPLC≼98% 01

Overview

Dihexa powder (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor.

1/4

www.wisepowder.com

wise12@wisepowder.com

02

Dihexa (PNB-0408) powder (1401708-83-5) video

03

Dihexa(PNB-0408) powder Base Information

Name

Dihexa/PNB-0408

CAS

1401708-83-5

Purity

98%

Chemical name

6-[(2S,3S)-2-[(2S)-2-hexanamido-3-(4-hydroxyphenyl)propana mido]-3-methylpentanamido]hexanamide

Synonyms

PNB-0408; PNB 0408; PNB0408; Dihexa; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide; N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucina mide

Molecular Formula

C27H44N4O5

Molecular Weight

504.672

Melting Point

>209°C (dec.)

InChI Key

XEUVNVNAVKZSPT-JTJYXVOQSA-N

Form

Solid powder

Appearance

White to Off-White Solid

Half Life

Unknow

Solubility

DMSO (Slightly), Methanol (Slightly)

Storage Condition

Hygroscopic, Refrigerator, under inert atmosphere

Application

N-Hexanoic-Try-Ile-(6)-amino Hexanoic amide (Dihexa) is an angiotensin IV analog as a procognitive/antidementia agent.

Testing Document

Available

04

Dihexa (PNB-0408) General Description

Dihexa powder, an oligopeptide drug, is a stable bioavailable synthetic Hepatocyte growth factor (HGF) mimetic with potential to improve cognitive function in animal models of Alzheimer’s disease-like mental impairment. Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog; exhibits high affinity binding hepatocyte growth factor (HGF) with a Kd of 65 pM. In Vitro: Dihexa powder binds with high affinity to HGF and both dihexa and its parent compound Norleucine 1-AngIV induce c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.

Further, dihexa and Nle1-AngIV induce hippocampal spinogenesis and 2/4

www.wisepowder.com

wise12@wisepowder.com

synaptogenesis similar to HGF itself. Dihexa effectively inhibits HGF dimerization at 1 μM. While dihexa at 1 nM and 10 pM alone does not activate c-Met, it markedly augments the capacity of HGF at 1.25 and 2.5 ng/mL to activate c-Met. In Vivo: Dihexa has a long circulating half-life. Dihexa exhibits procognitive activity.

Dihexa reverses scopolamine-dependent spatial learning deficits. It improves spatial learning in aged rats. Dihexa induces spinogenesis in cultured hippocampal neurons.

05

Dihexa (PNB-0408) powder History

Dihexa powder is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. Dihexa is a nooptropic and a small peptide that has been developed by researchers from Washington State University to potently improve certain cognitive function of potential trauma-based brain disorders and neurodegenerative conditions such as Alzheimer’s through increased synaptogenesis.

06

Dihexa (PNB-0408) Mechanism Of Action

Dihexa powder is a first-in-class compound that is orally active, penetrates the blood-brain barrier, and facilitates memory consolidation and retrieval. This angiotensin-based small molecule may be efficacious for AD. Harding, the designer of the drug Dihexa, says that they have quickly found out that this molecule is absolutely, insanely active. He further suggests that Dihexa or molecules like it may have applications in other neurodegenerative disease or brain traumas where neuronal connections are lost.

Dihexa powder also shows promise in overcoming memory and motor dysfunctions byaugmenting synaptic connectivity via the formation of new functional synapses.

07

Dihexa (PNB-0408) Application

Dihexa powder is an oligopeptide drug that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. Dihexa is a relatively new drug and basically this drug has been synthesized for the purpose of relieving people who have Alzheimer’s disease. So Dihexa’s primary reputation is as a potent nootropic supplement for those afflicted with Alzheimer’s Disease (AD). Whereas most Alzheimer’s drugs impede the progression of the disease, Dihexa repairs the damage in the synapse between neurons.

3/4

www.wisepowder.com

wise12@wisepowder.com

Users have reported increases in creative thinking, social intuition, and problem-solving skills. There has also been a fair deal of non-responders who haven’t felt anything at all.

It has also been considered as a prospective guard against aminoglycoside toxicity in hair cells. The outcome of this test found that Dihexa provided optimal protection against severe treatment with otoxin.

08

Dihexa (PNB-0408) More Research

In an assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. Dihexa has also been called a “neurogenic wonder-drug” and the drug can be ten million times stronger than BDNF (Brain-derived neurotrophic factor), one of the leading medications for new synapse formation.

09

Dihexa (PNB-0408) Document Download

COA

10

Dihexa (PNB-0408) Reference



Benoist CC, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014 Nov;351(2):390-402



Mathapati S, Siller R, Impellizzeri AA, Lycke M, Vegheim K, Almaas R, Sullivan GJ. Small-Molecule-Directed Hepatocyte-Like Cell Differentiation of Human Pluripotent Stem Cells. Curr Protoc Stem Cell Biol. 2016 Aug 17;38:1G.6.1-1G.6.18. doi: 10.1002/cpsc.13.

PubMed PMID: 27532814.



Siller R, Greenhough S, Naumovska E, Sullivan GJ. Small-molecule-driven hepatocyte differentiation of human pluripotent stem cells. Stem Cell Reports. 2015 May 12;4(5):939-52. doi: 10.1016/j.stemcr.2015.04.001. PubMed PMID: 25937370; PubMed Central PMCID: PMC4437467.

4/4